Inogen (NASDAQ:INGN) Stock Rating Reaffirmed by Needham & Company LLC

Inogen (NASDAQ:INGN)‘s stock had its “hold” rating reaffirmed by Needham & Company LLC in a research report issued on Tuesday, Benzinga reports.

Separately, William Blair raised shares of Inogen from a “market perform” rating to an “outperform” rating in a research note on Thursday, February 15th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, Inogen has a consensus rating of “Hold” and a consensus price target of $13.67.

Inogen Price Performance

Shares of NASDAQ INGN opened at $7.40 on Tuesday. The company has a market cap of $172.64 million, a P/E ratio of -1.68 and a beta of 1.06. Inogen has a 1 year low of $4.13 and a 1 year high of $14.10. The firm has a 50-day simple moving average of $7.67 and a two-hundred day simple moving average of $6.21.

Inogen (NASDAQ:INGN) last announced its quarterly earnings data on Tuesday, February 27th. The medical technology company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.49). The firm had revenue of $75.90 million during the quarter, compared to the consensus estimate of $78.09 million. Inogen had a negative return on equity of 38.98% and a negative net margin of 32.46%. As a group, equities research analysts expect that Inogen will post -2.56 EPS for the current year.

Hedge Funds Weigh In On Inogen

Several institutional investors and hedge funds have recently bought and sold shares of the company. US Bancorp DE grew its holdings in shares of Inogen by 273.0% during the first quarter. US Bancorp DE now owns 884 shares of the medical technology company’s stock valued at $28,000 after buying an additional 647 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Inogen by 84.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,288 shares of the medical technology company’s stock valued at $29,000 after buying an additional 2,419 shares during the last quarter. Captrust Financial Advisors grew its holdings in shares of Inogen by 124.7% during the first quarter. Captrust Financial Advisors now owns 993 shares of the medical technology company’s stock valued at $32,000 after buying an additional 551 shares during the last quarter. FMR LLC grew its holdings in shares of Inogen by 415.1% during the third quarter. FMR LLC now owns 7,907 shares of the medical technology company’s stock valued at $41,000 after buying an additional 6,372 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its holdings in shares of Inogen by 2,918.3% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,908 shares of the medical technology company’s stock valued at $43,000 after buying an additional 7,646 shares during the last quarter. 89.94% of the stock is owned by hedge funds and other institutional investors.

Inogen Company Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.